Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

NCT05216965 is registered in ClinicalTrials.gov with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor.

NCT NCT05216965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 11, 2022
Completion date
December 31, 2025
Enrollment
208 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors